Mass Spectrometry Driven Biophysical Characterization of Antibodies and Antibody–Drug Conjugates

About this webinar

Monoclonal antibody discovery aims to produce mAb with high specificity, affinity, and suitable biophysical properties against a chosen antigen.

Biophysical characterization of mAb is critical because it links an antibody’s structure and physicochemical properties directly to its safety, efficacy, and developability as a therapeutic or research reagent. Without it, promising candidates often fail later due to instability, aggregation, or poor binding behavior that could have been detected early. It also demonstrates process control and product understanding, which is essential for approval of new antibodies and biosimilars.

We will showcase in this webinar how we use mass spectrometry to characterize mAbs and derivatives including intact mass, middle up, bottom up as well as in higher order structure with epitope/paratope mapping and non-covalent binding monitoring. Finally, a special focus will be put on ADC characterization (cys-linked: partially non covalent ADCs) by MS and pharmacological approaches.

The webinar will take place at:

5.00 p.m. BST (UK, Lisbon)
6.00 p.m. CEST (Paris, Madrid, Frankfurt etc.)
12.00 p.m. EDT (New York, Boston)
9.00 a.m. PDT (San Francisco, LA)

Learning objectives

· Understand how mass spectrometry is applied to characterize monoclonal antibodies (mAbs), from intact to bottom-up approaches
· Learn how to analyze higher-order structures, including epitope/paratope mapping and non-covalent interactions
· Explore methods to monitor binding and structural integrity of antibody-based therapeutics using MS
· Gain insights into the characterization of antibody–drug conjugates (ADCs), including cysteine-linked and partially non-covalent species

If you are unable to attend the ZOOM webinar, you can still register to access the replay.

Discover our speaker

This webinar will be presented by:

Dr François Debaene
Head of Mass Spectrometry
François Debaene is Head of Mass Spectrometry at Novalix, a position he has held for 7 years. With over 15 years of expertise in mass spectrometry (MS), particularly structural MS, he has supported numerous drug discovery projects in the biopharmaceutical and CRO sectors.
He obtained his PhD at the University of Strasbourg on PNA-encoded library, followed by postdoctoral work in structural MS at LSMBO/CNRS and a position at Sanofi Paris as Deputy Head of the Structural Analysis Laboratory.
Since 2017, François has built and led the MS team at Novalix, implementing advanced approaches surch as HDX-MS and SEC-UV-native MS for structural studies, as well as covalent and non-covalent screening approaches, including binding site identification for soluble or membrane proteins.
He has authored over 40 publications and oral communications, and currently manages a team of six scientists and three dedicated MS systems.

Organizer: iBody Inc.